 |
43 Diseases |  |
5 Trials |
|
5 Trials |  |
3073 News |  |
| «12345678 |
- | adomeglivant (LY2409021) / Eli Lilly
Trial completion: The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream (clinicaltrials.gov) - Nov 26, 2013
P1, N=45, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed
- adomeglivant (LY2409021) / Eli Lilly
Enrollment change: The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream (clinicaltrials.gov) - Sep 15, 2013
P1, N=45, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed N=30 --> 45
- gemfibrozil / Generic mfg.
Enrollment change: Initial Screening of Gemfibrozil as a Novel Treatment for Tobacco Addiction (clinicaltrials.gov) - Aug 20, 2013
P2, N=40, Recruiting, Sponsor: Centre for Addiction and Mental Health
N=30 --> 45 N=60 --> 40
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
New P1 trial: Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and Itraconazole (clinicaltrials.gov) - Jul 30, 2013
P1, N=41, Completed, Sponsor: Astellas Pharma Europe BV
- | gemfibrozil / Generic mfg.
New P1/2 trial: Gemfibrozil for Smoking Cessation (clinicaltrials.gov) - Jul 14, 2013
P1/2, N=60, Recruiting, Sponsor: National Institute on Drug Abuse (NIDA)
- gemfibrozil / Generic mfg.
New P2 trial: Initial Screening of Gemfibrozil as a Novel Treatment for Tobacco Addiction (clinicaltrials.gov) - Jun 11, 2013
P2, N=40, Recruiting, Sponsor: Centre for Addiction and Mental Health
- | Tafinlar (dabrafenib) / Novartis
Trial completion: A study to test possible drug interactions with a new drug for treating skin cancer. (EUDRACT) - Apr 19, 2013
P2, N=48, Completed, Sponsor: GlaxoSmithKline Research and Development Limited
N=60 --> 40 Ongoing --> Completed
- | adomeglivant (LY2409021) / Eli Lilly
New P1 trial: The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream (clinicaltrials.gov) - Apr 17, 2013
P1, N=45, Completed, Sponsor: Eli Lilly and Company
- | ASP3652 / Autobahn Therap
New P1 trial: A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects (clinicaltrials.gov) - Feb 20, 2013
P1, N=48, Completed, Sponsor: Astellas Pharma Europe BV
- | evacetrapib (LY2484595) / Eli Lilly
Trial completion: A Study of Evacetrapib in Healthy Participants (clinicaltrials.gov) - Feb 13, 2013
P1, N=24, Completed, Sponsor: Eli Lilly and Company
Ongoing --> Completed Active, not recruiting --> Completed
- || Tafinlar (dabrafenib) / Novartis
Trial initiation date: A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors (clinicaltrials.gov) - Jan 9, 2013
P1, N=60, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Initiation date: Jul 2011 --> Sep 2012
- || Tafinlar (dabrafenib) / Novartis
Enrollment change: A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors (clinicaltrials.gov) - Dec 18, 2012
P1, N=60, Completed, Sponsor: GlaxoSmithKline
Initiation date: Jul 2011 --> Sep 2012 N=48 --> 60
- ||| Tafinlar (dabrafenib) / Novartis
Trial completion: A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors (clinicaltrials.gov) - Dec 18, 2012
P1, N=60, Completed, Sponsor: GlaxoSmithKline
N=48 --> 60 Recruiting --> Completed
- | evacetrapib (LY2484595) / Eli Lilly
New P1 trial: A Study of Evacetrapib in Healthy Participants (clinicaltrials.gov) - Nov 27, 2012
P1, N=24, Completed, Sponsor: Eli Lilly and Company
- gemfibrozil / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change: GEM-PK: Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil (clinicaltrials.gov) - Mar 12, 2012
P=N/A, N=15, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Completed N=30 --> 15
- | Tafinlar (dabrafenib) / Novartis
New P2 trial: A study to test possible drug interactions with a new drug for treating skin cancer. (EUDRACT) - Mar 1, 2012
P2, N=48, Completed, Sponsor: GlaxoSmithKline Research and Development Limited
- gemfibrozil / Generic mfg.
Trial completion: Effect of Gemfibrozil on the Safety and Pharmacokinetics of Red Yeast Rice in Healthy Subjects (clinicaltrials.gov) - Oct 13, 2011
P4, N=12, Completed, Sponsor: National Taiwan University Hospital
N=30 --> 15 Not yet recruiting --> Completed